• Je něco špatně v tomto záznamu ?

Balloon-expandable transcatheter aortic valve implantation with or without pre-dilation - results of a meta-analysis of 3 multicenter registries

JO. Ashauer, N. Bonaros, M. Kofler, G. Schymik, C. Butter, M. Romano, V. Bapat, J. Strauch, H. Schröfel, A. Busjahn, C. Deutsch, P. Bramlage, J. Kurucova, M. Thoenes, S. Baldus, TK. Rudolph,

. 2019 ; 19 (1) : 172. [pub] 20190719

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, metaanalýza, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20023816

BACKGROUND: To evaluate the outcomes of transcatheter aortic valve implantation (TAVI) without balloon aortic valvuloplasty (BAV) in a real-world setting through a patient-level meta-analysis. METHODS: The meta-analysis included patients of three European multicenter, prospective, observational registry studies that compared outcomes after Edwards SAPIEN 3 or XT TAVI with (n = 339) or without (n = 355) BAV. Unadjusted and adjusted pooled odds ratios (with 95% confidence intervals) were calculated for procedural and 30-day outcomes. RESULTS: Median procedural time was shorter in the non-BAV group than in the BAV group (73 versus 93 min, p = 0.001), as was median fluoroscopy time (7 versus 11 min, p = 0.001). Post-delivery balloon dilation (15.5% versus 22.4%, p = 0.02) and catecholamine use (9.0% vs. 17.9%; p = 0.016) was required less often in the non-BAV group than in the BAV group with the difference becoming insignificant after multiple adjustment. There was a reduced risk for periprocedural atrioventricular block during the intervention (1.4% versus 4.1%, p = 0.035) which was non-significant after adjustment. The rate of moderate/severe paravalvular regurgitation post-TAVI was 0.6% in the no-BAV group versus 2.7% in the BAV group. There were no between-group differences in the risk of death, stroke or other adverse clinical outcomes at day 30. CONCLUSIONS: This patient-level meta-analysis of real-world data indicates that TAVI performed without BAV is advantageous as it has an adequate device success rate, reduced procedure time and no adverse effects on short-term clinical outcomes.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20023816
003      
CZ-PrNML
005      
20201214131314.0
007      
ta
008      
201125s2019 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s12872-019-1151-y $2 doi
035    __
$a (PubMed)31324150
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Ashauer, Jannik Ole $u Department of Cardiology, University of Cologne Heart Center, Cologne, Germany.
245    10
$a Balloon-expandable transcatheter aortic valve implantation with or without pre-dilation - results of a meta-analysis of 3 multicenter registries / $c JO. Ashauer, N. Bonaros, M. Kofler, G. Schymik, C. Butter, M. Romano, V. Bapat, J. Strauch, H. Schröfel, A. Busjahn, C. Deutsch, P. Bramlage, J. Kurucova, M. Thoenes, S. Baldus, TK. Rudolph,
520    9_
$a BACKGROUND: To evaluate the outcomes of transcatheter aortic valve implantation (TAVI) without balloon aortic valvuloplasty (BAV) in a real-world setting through a patient-level meta-analysis. METHODS: The meta-analysis included patients of three European multicenter, prospective, observational registry studies that compared outcomes after Edwards SAPIEN 3 or XT TAVI with (n = 339) or without (n = 355) BAV. Unadjusted and adjusted pooled odds ratios (with 95% confidence intervals) were calculated for procedural and 30-day outcomes. RESULTS: Median procedural time was shorter in the non-BAV group than in the BAV group (73 versus 93 min, p = 0.001), as was median fluoroscopy time (7 versus 11 min, p = 0.001). Post-delivery balloon dilation (15.5% versus 22.4%, p = 0.02) and catecholamine use (9.0% vs. 17.9%; p = 0.016) was required less often in the non-BAV group than in the BAV group with the difference becoming insignificant after multiple adjustment. There was a reduced risk for periprocedural atrioventricular block during the intervention (1.4% versus 4.1%, p = 0.035) which was non-significant after adjustment. The rate of moderate/severe paravalvular regurgitation post-TAVI was 0.6% in the no-BAV group versus 2.7% in the BAV group. There were no between-group differences in the risk of death, stroke or other adverse clinical outcomes at day 30. CONCLUSIONS: This patient-level meta-analysis of real-world data indicates that TAVI performed without BAV is advantageous as it has an adequate device success rate, reduced procedure time and no adverse effects on short-term clinical outcomes.
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a aortální chlopeň $x diagnostické zobrazování $x patofyziologie $x chirurgie $7 D001021
650    _2
$a aortální stenóza $x diagnostické zobrazování $x mortalita $x patofyziologie $x chirurgie $7 D001024
650    12
$a balónková valvuloplastika $x škodlivé účinky $7 D063126
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a srdeční chlopně umělé $7 D006350
650    _2
$a hemodynamika $7 D006439
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a multicentrické studie jako téma $7 D015337
650    _2
$a pozorovací studie jako téma $7 D064887
650    _2
$a pooperační komplikace $x etiologie $x mortalita $7 D011183
650    _2
$a protézy - design $7 D011474
650    _2
$a registrace $7 D012042
650    _2
$a hodnocení rizik $7 D018570
650    _2
$a rizikové faktory $7 D012307
650    _2
$a časové faktory $7 D013997
650    12
$a transkatetrální implantace aortální chlopně $x škodlivé účinky $x přístrojové vybavení $x mortalita $7 D065467
650    _2
$a výsledek terapie $7 D016896
651    _2
$a Evropa $7 D005060
655    _2
$a časopisecké články $7 D016428
655    _2
$a metaanalýza $7 D017418
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Bonaros, Nikolaos $u Department of Cardiac Surgery, Medical University Innsbruck, Innsbruck, Austria.
700    1_
$a Kofler, Markus $u Department of Cardiac Surgery, Medical University Innsbruck, Innsbruck, Austria.
700    1_
$a Schymik, Gerhard $u Medical Clinic IV, Department of Cardiology, Municipal Hospital, Karlsruhe, Germany.
700    1_
$a Butter, Christian $u Department of Cardiology, Immanuel Clinic Bernau, Heart Center Brandenburg, Bernau, Germany.
700    1_
$a Romano, Mauro $u Institut Hospitalier Jacques Cartier, Massy, France.
700    1_
$a Bapat, Vinayak $u Columbia University Medical Center / New York-Presbyterian Hospital, New York, NY, USA.
700    1_
$a Strauch, Justus $u Clinic for Cardiosurgery and Thoracic Surgery, Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil, Bochum, Germany.
700    1_
$a Schröfel, Holger $u Department Cardiovascular Surgery, University Heart Center Freiburg, Bad Krozingen, Germany.
700    1_
$a Busjahn, Andreas $u Healthtwist GmbH, Berlin, Germany.
700    1_
$a Deutsch, Cornelia $u Institute for Pharmacology and Preventive Medicine, Bahnhofstrasse 20, 49661, Cloppenburg, Germany.
700    1_
$a Bramlage, Peter $u Institute for Pharmacology and Preventive Medicine, Bahnhofstrasse 20, 49661, Cloppenburg, Germany. peter.bramlage@ippmed.de.
700    1_
$a Kurucova, Jana $u Edwards Lifesciences, Medical Affairs/Professional Education, Prague, Czech Republic.
700    1_
$a Thoenes, Martin $u Edwards Lifesciences, Medical Affairs/Professional Education, Nyon, Switzerland.
700    1_
$a Baldus, Stephan $u Department of Cardiology, University of Cologne Heart Center, Cologne, Germany.
700    1_
$a Rudolph, Tanja K $u Department of Cardiology, University of Cologne Heart Center, Cologne, Germany. Department of Cardiology, Heart and Diabetes Center Bad Oeynhausen, Ruhr-University of Bochum, Bad Oeynhausen, Germany.
773    0_
$w MED00006809 $t BMC cardiovascular disorders $x 1471-2261 $g Roč. 19, č. 1 (2019), s. 172
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31324150 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201214131312 $b ABA008
999    __
$a ok $b bmc $g 1596135 $s 1114492
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 19 $c 1 $d 172 $e 20190719 $i 1471-2261 $m BMC cardiovascular disorders $n BMC Cardiovasc Disord $x MED00006809
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Možnosti archivace